Bob Jahr is the Chief Executive Officer (CEO) of Outlook Therapeutics, a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, including wet AMD.